Thu Dec 26 06:52:22 UTC 2024: ## Senores Pharmaceuticals IPO Oversubscribed, Allotment Finalized

**Mumbai, December 26, 2024** – Senores Pharmaceuticals’ Initial Public Offering (IPO) has been massively oversubscribed, closing at 93.41 times its offered shares. The three-day bidding period, which ended yesterday, saw strong interest from all investor categories. The IPO raised a total of Rs 582.11 crore, comprising a fresh issue of Rs 500 crore and an offer for sale of up to 21 lakh equity shares.

The allotment of shares will be finalized today, December 26th, with successful applicants notified via SMS, email, or online alerts by Friday, December 27th. Investors can check their allotment status through the BSE website or the Link Intime India portal, the IPO’s registrar.

The IPO, priced between Rs 372 and Rs 391 per share, saw particularly strong demand from Non-Institutional Investors (NIIs) at 96.11 times subscription and Qualified Institutional Buyers (QIBs) at 94.66 times. Retail investor subscription was also impressive at 89.23 times.

Even before listing, Senores Pharmaceuticals shares are trading at a significant premium in the grey market, currently commanding a premium of Rs 240 above the upper price band. This suggests a potential listing price of Rs 631 on Monday, December 30th, when the shares are set to debut on the NSE and BSE.

Founded in December 2017, Senores Pharmaceuticals focuses on developing and manufacturing pharmaceutical products for regulated markets, including the US, Canada, and the UK. The company boasts a portfolio of 55 products in key therapeutic areas as of September 30, 2024.

Read More